Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
Alnylam Pharmaceuticals currently markets four approved drugs, generating significant revenue growth, and expects further top-line boosts from partnerships like Novartis's Leqvio. The company is advancing a promising pipeline with candidates like cemdisiran, zilebesiran, mivelsiran, and nucresiran, which are in various stages of clinical trials and have the potential to expand its commercial portfolio. Despite stiff competition for its lead drug Amvuttra and an expensive stock valuation, Alnylam is focused on long-term growth through its diversified pipeline.
ALNY - Alnylam Pharmaceuticals Inc Latest SEC Filings
This article provides the latest SEC filing information for Alnylam Pharmaceuticals Inc. (ALNY), along with comprehensive financial data, performance metrics, and key statistics. It includes details on market cap, enterprise value, income, sales, various ratios, insider transactions, institutional ownership, and price performance over different periods.
Enterprise value to revenue forward of Alnylam Pharmaceuticals, Inc – XETR:DUL
This article focuses on the "Enterprise value to revenue forward" metric for Alnylam Pharmaceuticals, Inc (XETR:DUL). It appears to be a financial data point presented on TradingView, indicating a specific valuation ratio for the company's future revenue. The content primarily lists navigation elements and disclaimers from the TradingView platform rather than providing a detailed analysis of the metric itself.
ALNY - Alnylam Pharmaceuticals Inc Volatility & Greeks
This article provides a detailed financial overview of Alnylam Pharmaceuticals Inc (ALNY), including its last closing price, market capitalization, sales, income, and various financial ratios. It also presents key performance indicators such as EPS growth, sales growth, insider/institutional ownership, profitability margins, and stock performance over different periods. The data aims to offer insights into the company's financial health, operational efficiency, and market valuation.
Price to book forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY
This article provides the "Price to book forward" metric for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). It appears to be a financial data snippet from TradingView, offering a specific valuation ratio for the company over a given period. The content is concise, focusing solely on this financial datum without further analysis or commentary.
Alnylam (ALNY) Has an RNAi Platform and TTR Franchise Bigger Than a One-Drug Biotech Label
Alnylam Pharmaceuticals (ALNY) is evolving beyond a single-product biotech, now recognized as a scaled RNAi platform with a dominant TTR franchise and growing rare-disease revenue streams. The company reported impressive Q1 2026 revenues of $1.167 billion, demonstrating significant year-over-year growth and GAAP and non-GAAP profitability in 2025. This robust performance, combined with a deep pipeline and ongoing clinical developments, indicates a shift towards financial durability and broader commercial footprint.
Komodo Expands Strategic Partnership with Alnylam Pharmaceuticals, Inc. (ALNY)
Komodo Health has expanded its strategic partnership with Alnylam Pharmaceuticals, Inc. (ALNY), building on Alnylam's previous adoption of Komodo's AI platform for commercial operations. This expansion aims to enhance decision-making, scale operations, and support sustainable growth for Alnylam. This follows Alnylam's earlier announcement of an AI collaboration with Inceptive Nucleics, valued at up to $2 billion, focusing on accelerating RNAi therapeutic discovery.
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Expanding Its Enterprise-Wide AI Analytics Partnership
Alnylam Pharmaceuticals has expanded its partnership with Komodo Health to integrate its Marmot AI analytics platform across its enterprise functions. This move, building on previous commercial use, aims to streamline decision-making and enhance insights, though it's seen more as an execution tool than a direct growth driver. While it could improve efficiency, it does not fundamentally alter the core risks associated with Alnylam's high valuation, clinical outcomes, and market competition.
Barclays Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $527
Barclays has reiterated its Buy rating for Alnylam Pharmaceuticals (ALNY.US), while simultaneously maintaining its target price at $527. This continued positive outlook from Barclays suggests confidence in the company's future performance.
Is Alnylam Pharmaceuticals (ALNY) Undervalued Following Its Expanded Komodo Health AI Partnership?
Alnylam Pharmaceuticals (ALNY) has expanded its AI partnership with Komodo Health, integrating Komodo's Marmot analytics AI platform across its enterprise functions. Despite its stock being under pressure, analysts suggest the company is undervalued with a fair value of $550, significantly higher than its last close of $291.37. Investors should consider potential risks like underperformance of AMVUTTRA and margin pressures, as well as the company's high P/E ratio compared to industry averages.
ALNY Maintains Buy Rating -- Price Target Lowered by HC Wainwrig
HC Wainwright & Co. has lowered its price target for Alnylam Pharmaceuticals (ALNY) to $470.00 from $510.00, but has maintained a 'Buy' rating. GuruFocus indicates that ALNY is significantly undervalued by approximately 43.3% with a GF Value™ of $513.74 compared to its current price of $291.37. The company boasts a strong GF Score™ of 74/100, driven by excellent growth prospects, despite lower financial strength and profitability ratings.
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Powerhouse with a Potential 49.75% Upside
Alnylam Pharmaceuticals, Inc. (ALNY) is highlighted as a biotech powerhouse specializing in RNA interference therapeutics with a market cap of $38.9 billion. The company shows strong financial health with 96.40% revenue growth and potential 49.75% upside based on analyst ratings. Despite recent stock dips, its robust pipeline and strategic collaborations position it for sustained growth, making it an appealing prospect for investors focused on capital appreciation rather than dividend yield.
Number of shareholders of Alnylam Pharmaceuticals, Inc – BX:DUL
This article focuses on the number of shareholders for Alnylam Pharmaceuticals, Inc (DUL) on BX Swiss. It provides market data, financial information, and links to SEC filings and other documents, all provided by various financial data services. The content appears to be a stub or a section of a larger financial data page.
Price to sales forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY
This article displays the "Price to sales forward" metric for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on TradingView. It indicates that the data is provided by ICE Data Services and FactSet, with SEC filings from Quartr. The core content is limited to this financial data point.
Enterprise value to EBITDA forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY
This article provides financial information for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), specifically focusing on its enterprise value to EBITDA forward metric. It details where the data is sourced from and indicates the market is currently closed with no trades.
Alnylam Pharmaceuticals, Inc Actuals & Estimates (NASDAQ:ALNY)
This article provides an in-depth view of Alnylam Pharmaceuticals, Inc. (ALNY) financial data and analyst estimates, including its current stock price, historical performance, and future forecasts. It covers key financial metrics like earnings, revenue, net income, and market capitalization, along with frequently asked questions about the company's stock.
Enterprise value to EBIT forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY
This article provides the enterprise value to EBIT forward for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). It appears to be a financial data point from TradingView, a platform offering financial market tools and information. The content primarily states this specific financial metric without further elaborated analysis.
Komodo Health Expands Strategic Partnership with Alnylam Pharmaceuticals to Scale Marmot Analytics Ai Platform
Komodo Health has expanded its strategic partnership with Alnylam Pharmaceuticals to integrate Komodo's AI-powered analytics platform, Marmot, across various enterprise functions at Alnylam. This collaboration aims to provide Alnylam with real-time, transparent healthcare intelligence, moving beyond fragmented analytical tools. The platform will support data-driven decision-making, optimize operational objectives, and enhance patient impact.
Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh
This article provides access to the "Enterprise value to EBIT forward" metric for Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh (A1LN34) on the BMFBOVESPA exchange. It highlights the company's financial data available on TradingView, serving as a data point for investors researching the pharmaceutical company.
Alnylam expands AI partnership with Komodo Health
Alnylam Pharmaceuticals has expanded its AI partnership with Komodo Health, extending the deployment of the Marmot analytics AI platform across its customer-facing organization and broader enterprise operations. The collaboration, which began in August 2025, aims to accelerate decision-making and sustainable growth, with Alnylam already seeing a reduction in reporting cycles from months to hours. This expansion comes as Alnylam demonstrates strong financial performance, with revenue surging 83% to $4.29 billion and achieving profitability.
Price to earnings forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY
This article provides financial information for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed with no trades at the time of the report. The content also briefly mentions the source of market and reference data, including ICE Data Services and FactSet.
Alnylam expands use of Komodo’s AI platform across its enterprise
Komodo Health and Alnylam Pharmaceuticals have expanded their strategic partnership, scaling Komodo's AI platform, Marmot™, across Alnylam's enterprise. Marmot, built on the Healthcare Map®, provides real-time, AI-powered intelligence to enhance decision-making and operational efficiency, moving beyond traditional fragmented analytics. This collaboration aims to unify data-driven insights and accelerate workflows in the life sciences sector.
Alnylam Pharmaceuticals (ALNY) Short Interest & Short Float | Updated Jun 2026 $ALNY
Alnylam Pharmaceuticals (ALNY) reported a short interest of 5.44 million shares as of June 15, 2026, representing 4.11% of its public float, which is a 2.59% increase from the previous report. The short interest ratio stands at 4.8 days to cover. This indicates a slight increase in bearish sentiment among investors, though the overall short interest percentage remains below significant levels that would suggest widespread negative sentiment.
AI-Driven RNAi Push and Nordic Expansion Might Change The Case For Investing In Alnylam (ALNY)
Alnylam Pharmaceuticals (ALNY) has recently expanded its commercial partnership with GENESIS Pharma into Scandinavian markets and initiated an AI-driven RNAi drug discovery collaboration with Inceptive Nucleics, valued at up to US$2.00 billion. These moves aim to broaden access to Alnylam's existing therapies and accelerate its drug discovery through AI, reinforcing its "Alnylam 2030" goals. While the AI collaboration is particularly significant for pipeline expansion, the article notes that investors should also be aware of potential pressure on pricing for AMVUTTRA.
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $370
Morgan Stanley has reiterated its "Hold" rating for Alnylam Pharmaceuticals (ALNY.US) and maintained its price target at $370. This indicates a consistent outlook from the firm regarding the company's stock performance.
AI-Driven RNAi Push and Nordic Expansion Might Change The Case For Investing In Alnylam (ALNY)
Alnylam Pharmaceuticals (ALNY) has expanded its commercial partnership with GENESIS Pharma into Nordic countries and entered an AI-driven drug discovery collaboration with Inceptive Nucleics, potentially worth up to US$2.00 billion. These moves aim to broaden access to Alnylam's existing RNAi therapies and accelerate its pipeline development through AI, reinforcing its long-term growth prospects. While analysts project significant revenue and earnings by 2028, investors should also consider potential pressures on AMVUTTRA pricing and the company's dependence on its TTR franchise.
Alnylam Pharmaceuticals, Inc. (ALNY) and GENESIS Pharma Expand Commercial Partnership
Alnylam Pharmaceuticals (ALNY) and GENESIS Pharma have expanded their commercial partnership to include Denmark, Finland, Norway, and Sweden, extending a collaboration that began in 2019 in Southeast Europe. This expansion grants GENESIS Pharma marketing rights for RNAi therapies targeting cardiomyopathy and rare genetic diseases across 17 markets. Separately, Alnylam formed a strategic AI partnership with Inceptive Nucleics, valued at up to $2 billion, to accelerate drug discovery by merging its RNAi platform with Inceptive’s AI models.
Alnylam Pharmaceuticals, Inc. (ALNY) and GENESIS Pharma Expand Commercial Partnership
Alnylam Pharmaceuticals, Inc. (ALNY) and GENESIS Pharma have expanded their commercial partnership to include Denmark, Finland, Norway, and Sweden, building on their existing collaboration in Southeast Europe. This expansion aims to improve access to RNAi therapies for cardiomyopathy and rare genetic diseases in a total of 17 markets. Additionally, Alnylam announced a strategic AI partnership with Inceptive Nucleics, valued at up to $2 billion, to accelerate drug discovery using AI-powered approaches paired with Alnylam's RNAi platform.
Alnylam Pharmaceuticals (ALNY), Inceptive Form $2B Partnership to Advance RNAi Drug Discovery
Alnylam Pharmaceuticals and Inceptive Nucleics have formed a partnership valued at up to $2 billion to accelerate the discovery of RNAi therapeutics. This collaboration combines Alnylam's RNAi platform and data with Inceptive's AI expertise and foundation models to enhance oligonucleotide designs and improve experimental productivity. The alliance aims to shorten drug discovery timelines and identify therapeutic candidates more efficiently, supporting Alnylam's "Alnylam 2030" pipeline expansion strategy.
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) has shown strong market outperformance over the last decade, with an annualized return of 17.65%. An initial investment of $100 made 10 years ago would now be worth $535.22, highlighting the significant impact of compounded returns. The company currently holds a market capitalization of $37.36 billion.
Oppenheimer Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $500
Oppenheimer has reiterated its Buy rating on Alnylam Pharmaceuticals (ALNY.US) and maintained a target price of $500. This indicates a continued positive outlook from the firm regarding Alnylam's stock performance.
Alnylam (ALNY) Expands Its RNAi Therapeutics Reach Into Four More Nordic Countries
Alnylam Pharmaceuticals, Inc. (ALNY) has expanded its commercial partnership with GENESIS Pharma to include Sweden, Finland, Denmark, and Norway, bringing its RNAi therapeutics for serious heart muscle diseases and rare genetic conditions to these new markets. This collaboration, which began in 2019 covering Southeast Europe, now extends Alnylam's reach to 17 markets. The expansion leverages Alnylam's proprietary RNAi technology, which silences disease-causing genes at a molecular level, and strengthens GENESIS Pharma's European footprint.
Alnylam (ALNY) Expands Its RNAi Therapeutics Reach Into Four More Nordic Countries
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) has expanded its commercial partnership with GENESIS Pharma to include Sweden, Finland, Denmark, and Norway. This expansion allows GENESIS Pharma to commercialize Alnylam’s RNAi therapeutics for serious heart muscle diseases and rare genetic conditions in these four new Nordic countries, building on their existing collaboration in Southeast Europe. Alnylam's RNAi technology aims to silence disease-causing genes, and this wider reach helps the company address the needs of more patients.
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
Alnylam Pharmaceuticals is heavily reliant on its drug Amvuttra, which accounts for 76% of its total revenues. To mitigate this dependence and intensify competition in the ATTR-CM market from rivals like Pfizer and BridgeBio, Alnylam is expanding its rare disease portfolio with drugs like Givlaari and Oxlumo, collaborating with Novartis on Leqvio, and advancing a diverse pipeline including treatments for neurodegenerative and cardiovascular diseases. The company's stock has underperformed this year, though its 2026 earnings estimates have improved.
Barclays Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $527
Barclays has reiterated its 'Buy' rating for Alnylam Pharmaceuticals (ALNY.US) and maintained its target price at $527. This
Alnylam Pharmaceuticals, Inc. (ALNY) Partners with Inceptive Nucleics to Accelerate Growth as A High-Growth Large-Cap Stock
Alnylam Pharmaceuticals (NASDAQ:ALNY) has partnered with Inceptive Nucleics in a strategic collaboration valued at up to $2 billion, including an upfront payment of $30 million. This partnership, which H.C. Wainwright reiterated with a Buy rating and $510 price target, is expected to accelerate therapeutic innovation and strengthen Alnylam's long-term growth under its ‘Alnylam 2030’ framework. The collaboration leverages Inceptive's AI-driven RNA drug design to reduce risks in drug discovery, furthering Alnylam’s pioneering work in RNA interference therapeutics.
Alnylam Pharmaceuticals Inc (ALNY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Alnylam Pharmaceuticals Inc (ALNY), categorizing its income by business segments and geographical regions. For FY2025, the company's leading product, AMVUTTRA, contributed 62.30% of revenue, with significant regional revenue coming from the United States (55.67%). The data also includes contributions from other products like GIVLAARI and OXLUMO, as well as revenue from collaborations and royalties, highlighting the diverse sources of the company's financial inflow.
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and Alnylam Pharma (ALNY)
Analysts from Truist Financial and J.P. Morgan have issued bullish sentiments on MBX Biosciences, Inc. (MBX) and Alnylam Pharma (ALNY), respectively. MBX Biosciences received a Buy rating with a $70 price target from Srikripa Devarakonda, while Jessica Fye reiterated a Buy rating on Alnylam Pharma. Both companies show strong buy consensus among analysts with significant upside potential from current levels.
Does Alnylam’s Generative AI Pact With Inceptive Nucleics Redraw The R&D Bull Case For ALNY?
Alnylam Pharmaceuticals has partnered with Inceptive Nucleics in a deal worth up to US$2.00 billion, integrating generative AI to enhance its RNAi drug discovery. This collaboration, which includes access to top AI talent, aims to boost Alnylam's R&D productivity and expand its pipeline, potentially reinforcing optimistic long-term growth forecasts, though the near-term focus remains on AMVUTTRA's commercial execution. The article encourages investors to weigh these AI-driven efforts against existing concentration and pricing risks.
Does Alnylam’s Generative AI Pact With Inceptive Nucleics Redraw The R&D Bull Case For ALNY?
Alnylam Pharmaceuticals has partnered with Inceptive Nucleics in a deal potentially worth $2 billion, integrating generative AI into its RNAi drug discovery to enhance R&D productivity. This collaboration, which includes access to top AI talent, aims to refine siRNA design using small biological datasets. While this AI integration and European expansion support Alnylam's growth narrative, the company's near-term focus remains on AMVUTTRA's market performance and pricing pressures, with the AI pact primarily bolstering its long-term pipeline development and R&D efficiency.
Alnylam Pharmaceuticals stock hits 52-week low at $282.71 By Investing.com
Alnylam Pharmaceuticals Inc. (ALNY) stock has fallen to a 52-week low of $282.71, marking a 27% decline year-to-date and a 7.67% drop over the past year, despite the company remaining profitable with diluted earnings of $3.95 per share. Analysts predict continued profitability, while InvestingPro’s Fair Value analysis suggests the stock is currently overvalued. The company recently reported strong first-quarter 2026 net product revenue of $1,036 million and announced a significant AI drug discovery collaboration with Inceptive Nucleics, valued up to $2 billion.
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced its tenth "RNAi Roundtable" webcast series, featuring presentations from Alnylam scientists and medical thought leaders. This series will highlight progress in pipeline programs such as ALN-6400, Zilebesiran, and ALN-HTT02, addressing conditions like bleeding disorders, hypertension, and Huntington’s disease. The initiative supports Alnylam’s 2030 goals of expanding its RNAi therapeutic pipeline to over 40 clinical programs and utilizing AI to accelerate discovery.
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
Alnylam Pharmaceuticals announced its tenth "RNAi Roundtable" webcast series, featuring presentations on pipeline programs like ALN-6400 for bleeding disorders and zilebesiran for blood pressure, as well as ALN-HTT02 for Huntington’s Disease. The company aims to expand its pipeline to over 40 clinical programs by 2030 and leverage AI to accelerate discovery, reinforcing its commitment to advancing RNAi therapeutics. These webcasts will provide insights into Alnylam's progress in RNAi therapeutics and its strategy to address unmet medical needs.
Alnylam Pharmaceuticals stock hits 52-week low at $282.71
Alnylam Pharmaceuticals (ALNY) stock has dropped to a 52-week low of $282.71, reflecting a 27% year-to-date decline and a challenging year for the company. Despite this, the company remains profitable with diluted earnings of $3.95 per share. Recent developments include a 121% increase in Q1 2026 net product revenue, a strategic AI drug discovery collaboration with Inceptive Nucleics, and an expanded commercial partnership with GENESIS Pharma in Nordic markets.
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced its tenth "RNAi Roundtable" webcast series, featuring presentations from Alnylam scientists and medical thought leaders on pipeline programs and unmet clinical needs. The series, which includes webcasts on ALN-6400, Zilebesiran, and ALN-HTT02, reaffirms Alnylam's commitment to advancing RNAi therapeutics and achieving its Alnylam 2030 goals of expanding its clinical pipeline and leveraging AI. The company aims to develop transformative medicines for serious diseases.
Andra AP fonden Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
Andra AP fonden significantly increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 134.5% during the fourth quarter, now holding 48,540 shares valued at $19.30 million. This move is part of a broader trend of institutional investment, with other major hedge funds also adjusting their positions in the biopharmaceutical company. Analysts currently rate ALNY as a "Moderate Buy" with a consensus target price of $463.13.
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As 2030 Goals And AI Partnership Refocus Growth Expectations
Alnylam Pharmaceuticals (ALNY) is back in focus due to its 2030 financial goals, the central role of AMVUTTRA, and a new AI partnership. Despite a year-to-date share price drop of 25.6%, the company's long-term returns remain strong, suggesting a potential mispricing as its valuation shows it as undervalued by analysts. However, its high P/E ratio compared to the industry indicates significant optimism already factored into the price.
Motley Fool Asset Management LLC Purchases 3,480 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
Motley Fool Asset Management LLC increased its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 38.5% in the fourth quarter, acquiring an additional 3,480 shares to a total of 12,526 shares valued at $4.98 million. Institutional investors collectively own 92.97% of the company's stock, with several major firms also adjusting their positions. Alnylam Pharmaceuticals reported strong quarterly results, with EPS of $1.99 against an $0.87 estimate and revenue of $1.17 billion, a 96.4% year-over-year increase.
GENESIS Pharma Broadens Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics Across Nordic Markets
GENESIS Pharma and Alnylam Pharmaceuticals have expanded their commercial partnership to include Denmark, Finland, Norway, and Sweden, in addition to thirteen existing Southeast European markets. This collaboration aims to commercialize RNAi therapeutics for serious cardiomyopathy and rare genetic diseases. Both companies emphasize their commitment to increasing patient access to innovative therapies across Europe.
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As 2030 Goals And AI Partnership Refocus Growth Expectations
Alnylam Pharmaceuticals (ALNY) is refocusing its growth expectations with 2030 goals and an AI partnership, despite a 25.6% year-to-date share price drop. While analysts suggest it's significantly undervalued based on earnings and cash flow, its high P/E ratio of 73.9x raises questions about current optimism. The valuation hinges on the success of AMVUTTRA and the wider TTR franchise.
